Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation

This study has been completed.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00433225
First received: February 7, 2007
Last updated: September 5, 2007
Last verified: September 2007

February 7, 2007
September 5, 2007
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00433225 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation
Not Provided

The purpose of this study was to evaluate the efficacy of ketorolac 0.4% on quality of vision and macula thickening in patients undergoing cataract surgery using the ReStor® multifocal IOL.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Macula Thickening
  • Drug: Prednisolone Acetate
  • Drug: Ketorolac 0.4%
  • Drug: Gatifloxacin 0.3%
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Males or females > 50 years old
  • Scheduled to undergo bilateral phacoemulsification with implantation of a multifocal IOL.
  • Likely to complete all study visits and able to provide informed consent
  • Visual potential of 20/25 or better

Exclusion Criteria:

  • · Prior use of topical ketorolac

    • Known contraindications to any study medication or ingredients
    • Active ocular diseases or uncontrolled systemic disease
    • Active ocular allergies
Both
50 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00433225
5293
Not Provided
Not Provided
Innovative Medical
Not Provided
Principal Investigator: Eric Donnenfeld Ophthalmic Consultants of Long Island
Innovative Medical
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP